• Validation of COVID-19 Vaccines Developed by Korea's Own Technology
    Author : 관리자
    Date : 2021.06.21
    Hit : 901
  • Research Team led by Prof. Nam Jae-hwan validated COVID-19 vaccine developed domestically


    The research team of Department of Medical Life Science, led by Professor Nam Jae-hwan, published the evaluation result of a new COVID-19 vaccine that SK Bioscience developed in ‘Science Advances (IF=13.117).’


    This vaccine is a protein-based synthetic antigen vaccine (RBD-P2) with enhanced immune response by binding tetanus toxoid epitope P2 to the RBD that couples with cell receptors (ACE2) at spike proteins of the coronavirus. At the same time, Prof. Nam’s team analyzed immune enhancing effect of the nucleocapsid protein of COVID-19 virus (SARS-CoV-2 nucleocapsid protein, N).


    All the synthetic antigen protein SK Bioscience used to develop the vaccine came from insect cells. They firstly mixed alum to a vaccine candidate (RBD-P2) as immune enhancer to make a vaccine (RBD-P2+Alum) and developed another type of vaccine where the nucleocapsid protein was additionally added (RBD-P2/N+Alum). When the two vaccine types were injected twice to monkeys, the team observed that the valence of neutralizing antibody reached 5 times higher with RBD-P2+Alum and 10 times higher with RBD-P2/N+Alum, compared to the patients in convalescent stages. It was also observed that the effects of the two vaccine types were sustained to 9 weeks from the vaccination, 1.5 times and 3 times higher than the patients, respectively. Additionally, the vaccine type with nucleocapsid protein (RBD-P2/N+Alum) caused cell-mediated immunity with a little higher level and removed the virus faster than the other.

  • Attachment File
Comment 0